Charles River Laboratories International (CRL) stock has surged 102.3% over the past year, trading around $294.44. This significant price appreciation raises questions regarding whether current valuations are fully supported by the company's underlying cash generation capabilities. Analysts project that CRL's annual Free Cash Flow will...
Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (CRL) by 0.1% during the first quarter, selling 2,280 shares to hold a remaining position of 1,993,316 shares valued at approximately $348.6 million. This holding represents about 0.6% of Allspring's total portfolio...
Charles River Laboratories International (CRL) is highlighted by Simply Wall St as potentially undervalued following a Morgan Stanley upgrade and a strategic collaboration with Eli Lilly's AI drug discovery platform, TuneLab. The article notes that CRL shares have gained momentum recently, posting a 15.41% return...
Charles River Laboratories (CRL) reported first-quarter revenue of $995.8 million, beating analyst estimates of $977.4 million with 1.2% year-on-year growth, while adjusted EPS reached $2.06 versus a consensus of $1.94, representing a 6% beat. The company highlighted that strategic divestitures, portfolio optimization, and cost-saving measures...
